IDEC’s 2002 Press Releases

by

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 | 2002 | 2001 |2000 | 1999 Back to main index

 

12/10/2002

Data On IDEC-114, an Investigational Antibody, for Patients With Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma Presented At American Society of Hematology Conference

11/12/2002

Updated Clinical Data in Zevalin Pivotal Trial for B-cell Non-Hodgkins Lymphoma Show Durable Remissions; Results Presented at Annual Society of Biological Therapy Meeting

10/16/2002

IDEC Pharmaceuticals Reports Third Quarter 2002 Results; Rituxan Sales Increase 31% Over 3Q 2001 and Earnings Increase to $0.22 Per Diluted Share

10/09/2002

IDEC Pharmaceuticals Announces Estimated Net Income of $0.22 Per Share in Third Quarter of 2002

10/09/2002

IDEC Pharmaceuticals Announces Clarification of Zevalin Medicare Reimbursement Status

09/30/2002

IDEC Pharmaceuticals and Nippon Shinyaku Sign License Agreement to Develop Novel, Anti-Cancer Drug

09/30/2002

IDEC Pharmaceuticals’ Chief Financial Officer to Retire After Fifteen and a Half Years of Service

09/17/2002

IDEC Pharmaceuticals and Caprion Pharmaceuticals Announce Drug Discovery Collaboration in Oncology

09/05/2002

IDEC Pharmaceuticals Announces Results of Phase II Clinical Trials of IDEC-114 Antibody in Psoriasis

07/17/2002

IDEC Pharmaceuticals Reports Second Quarter 2002 Results; Rituxan Sales Increase 43% Over 2Q 2001 and Earnings Increase to $0.20 Per Share

07/10/2002

IDEC Pharmaceuticals Announces Estimated Net Income of $0.20 Per Share in Second Quarter of 2002

07/01/2002

European Launch of Zevalin Radioimmunotherapy Delayed

06/10/2002

IDEC Pharmaceuticals Announces Medicare Reimbursement for the Zevalin Therapeutic Regimen Will Be Effective in October; Webcast Conference Call Today at 2:00 p.m. Pacific Time

06/10/2002

IDEC Pharmaceuticals Announces a Clinical Hold On Ongoing Clinical Trials of Its IDEC-131 Antibody; Webcast Conference Call Today at 2:00 p.m. Pacific Time

04/25/2002

IDEC Pharmaceuticals Announces Extension of Its Collaborative Agreement With Seikagaku Corporation for IDEC-152 In Allergic Asthma and Other Allergic Diseases

04/24/2002

IDEC To Receive $675 Million From Offering of Zero-Coupon Senior Convertible Notes

04/23/2002

IDEC Pharmaceuticals to Raise $675 Million From Offering of Zero-Coupon Senior Convertible Notes

04/18/2002

IDEC Pharmaceuticals Reports First Quarter 2002 Results; Rituxan Sales Increase 40% Over 1Q 2001 and Earnings Increase to $0.17 Per Share On a Diluted Basis

04/09/2002

IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales of $235 Million in First Quarter of 2002

04/08/2002

IDEC Pharmaceuticals Announces First Quarter Earnings Conference Call; Thursday, April 18, 2002, 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time

03/25/2002

IDEC Pharmaceuticals Launches First Radioimmunotherapy; Novel Cancer Therapy Zevalin Now Commercially Available in the United States

02/19/2002

Zevalin Therapeutic Regimen Receives FDA Marketing Approval; First Radioimmunotherapy Approved by FDA
01/29/2002

Fourth Consecutive Year of Profitability Reported by IDEC Pharmaceuticals; Revenue Growth of 76 Percent for Year 2001

01/16/2002

IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales for 2001: $226 Million in Fourth Quarter and $779 Million for the Full Year

01/10/2002

IDEC Pharmaceuticals Announces Promotion and Additions to Management and Board

01/08/2002

IDEC Pharmaceuticals Receives Zevalin BLA Complete Review Letter From FDA

01/07/2002

IDEC Pharmaceuticals Expects to Receive Zevalin BLA Complete Review Letter From FDA; Product Is Approvable Pending Resolution of Issues at Contract Manufacturer

01/07/2002

IDEC Pharmaceuticals And ExonHit Therapeutics Announce Collaborative Agreement in Target Discovery

2003 | 2002 |2001 |2000 |1999 Back to main index